Common Liver Injury Symptoms with Tigecycline
Tigecycline, a glycylcycline antibiotic used for complicated infections, can cause drug-induced liver injury (DILI) in some patients. Symptoms typically appear within days to weeks of starting treatment and often resolve after discontinuation. Common signs mirror acute hepatitis and include:
- Nausea and vomiting
- Abdominal pain, especially in the upper right quadrant
- Fatigue and weakness
- Jaundice (yellowing of skin or eyes)
- Dark urine
- Pale or clay-colored stools
- Loss of appetite
These stem from elevated liver enzymes like ALT, AST, and bilirubin, reported in post-marketing surveillance and clinical trials.[1][2]
How Tigecycline Causes Liver Issues
It disrupts hepatocyte function, leading to cholestasis or hepatocellular injury. Risk rises with higher doses, prolonged use (>14 days), or pre-existing liver conditions. Liver function tests (LFTs) often show 3-5x upper limit elevations, rarely progressing to severe failure.[3]
Monitoring and When to Seek Care
Doctors check LFTs before, during (days 3-5 and 14), and after therapy. Stop tigecycline if ALT >5x normal or symptoms emerge. Patients with symptoms should get immediate medical evaluation to rule out other causes like viral hepatitis.[1][4]
Frequency and Risk Factors
Liver-related adverse events occur in 1-10% of users, per FDA labeling—mostly mild and reversible. Higher risks in older adults, those with biliary obstruction, or concurrent hepatotoxins. No deaths directly linked in major trials, but monitor closely in ICU settings.[2][3]
Compared to Other Antibiotics
Tigecycline's hepatotoxicity rate (up to 8% enzyme elevations) exceeds tetracyclines like doxycycline (<2%) but is lower than some like telithromycin. It's flagged in DILI registries more than expected for its class.[4]
[1]: FDA Tigecycline Label
[2]: Hepatotoxicity of Antibiotics - LiverTox
[3]: Tigecycline Safety Profile - Clinical Review
[4]: Drug-Induced Liver Injury Network Data